Investigation of the Effect of Adopting Budesonide Suspension Combined with Compound Ipratropium Bromide Nebulized Inhalation Treatment in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Dis-ease
Objective To investigate the effect of budesonide suspension and compound ipratropium bromide com-bined with nebulized inhalation application in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease(COPD).Methods 107 patients with acute exacerbation of chronic obstructive pulmonary disease(COPD)admitted to Yixing Guanlin Hospital from January 2020 to December 2023 were conveniently selected as the study subjects,and they were divided into the study group(n=54)and the control group(n=53)by the odd-even method.The control group used nebulized inhalation budesonide suspension,and the study group used the combina-tion regimen of nebulized inhalation budesonide suspension and compound ipratropium bromide nebulized inhalation.The efficacy,adverse reactions,lung function indexes,blood gas indexes and inflammatory factor levels of the two groups were compared.Results The total therapeutic efficacy rate of the study group was 98.15%,which was higher than that of the control group 84.91%,and the difference was statistically significant(x2=6.089,P=0.014).Compari-son of the incidence of adverse reactions between the two groups,the difference was not statistically significant(P>0.05).After treatment,the study group's lung function indexes,blood gas levels,and inflammatory factor levels were better than those of the control group,and the differences were statistically significant(all P<0.05).Conclusion Nebu-lized inhalation of budesonide suspension and compound ipratropium bromide can reduce the symptoms and signs of patients with acute exacerbation of chronic obstructive pulmonary disease,improve lung function and blood gas in-dexes,and at the same time reduce the inflammatory response,with remarkable clinical effect and high safety of medi-cation.
NETL
NSTL
万方数据
